Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 6/20 | 0.50 |
| ▸ | DRD2 | P14416 | 6/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.50 |
| ▸ | DRD4 | P21917 | 4/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 3/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4090351 | 0.82 | CHRM1 (0.53) | CHRM1DRD2CHRM5CHRM3CHRM2 | |
| SCHEMBL5338969 | 0.81 | CDK4 (0.55) | CHRM1DRD2CHRM5CHRM3CHRM2 | |
| SCHEMBL30628011 | 0.79 | MEN1 (0.64) | TSHRKDM4ETP53MEN1KMT2A | |
| SCHEMBL4220374 | 0.79 | MEN1 (0.64) | TSHRKDM4ETP53MEN1KMT2A | |
| SCHEMBL14411753 | 0.79 | CHRM1 (0.50) | CHRM1DRD2CHRM5CHRM3CHRM2 | |
| SCHEMBL9775976 | 0.78 | FPR3 (0.58) | HRH3TSHRKDM4ETP53FPR3 | |
| SCHEMBL6326696 | 0.77 | MEN1 (0.58) | TSHRKDM4ETP53MEN1KMT2A | |
| SCHEMBL30151601 | 0.77 | MEN1 (0.58) | TSHRKDM4ETP53MEN1KMT2A | |
| SCHEMBL5336821 | 0.77 | MCHR1 (0.56) | HRH3KCNH2KDM4ETP53 | |
| SCHEMBL4106718 | 0.77 | CHRM1 (0.45) | CHRM1DRD2CHRM5CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113357-A1 | Muscarinic agonists | ANDERSON CARL-MAGNUS A (DK) | 2005-05-26 | — | — | US | claimed |
| US-20020037886-A1 | Muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2002-03-28 | — | — | US | claimed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007079239-A2 | BICYCLIC NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155795-A1 | MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-7238713-B2 | Muscarinic agonists | ACADIA PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1535912-A1 | Muscarinic agonists | Arcadia Pharmaceuticals Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20050113357-A1 | Muscarinic agonists | ANDERSON CARL-MAGNUS A (DK) | 2005-05-26 | — | — | US | disclosed |
| EP-1278741-B1 | MUSCARINIC AGONISTS | ACADIA PHARM INC (US) | 2005-03-02 | — | — | EP | disclosed |
| US-6627645-B2 | Cholinergic agents | ACADIA PHARMACEUTICALS, INC. | 2003-09-30 | — | — | US | disclosed |
| EP-1278741-A1 | MUSCARINIC AGONISTS | Acadia Pharmaceuticals Inc. (US) | 2003-01-29 | — | — | EP | disclosed |
| US-20020037886-A1 | Muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2002-03-28 | — | — | US | disclosed |
| WO-2001083472-A1 | MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | CHRM1 1153/4885DRD2 2688/4885CHRM5 1148/4885 |
| US-20020037886-A1 | Muscarinic agonists | CHRM2, CHRM1, CHRM4 | CHRM1 2/4885DRD2 476/4885CHRM5 5/4885 |
| US-20070155795-A1 | MUSCARINIC AGONISTS | CHRM2, CHRM1, CHRM4 | CHRM1 2/4885DRD2 476/4885CHRM5 5/4885 |
| US-20050113357-A1 | Muscarinic agonists | CHRM2, CHRM1, CHRM4 | CHRM1 2/4885DRD2 476/4885CHRM5 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.